ImmunoGen, Inc. Expands Pipeline of Targeted Anticancer Compounds
Company to Develop TAP Compound to Novel Target Using Centocor Antibody
08-Jan-2008 -
ImmunoGen, Inc. announced that it has licensed the exclusive right to develop and commercialize a TAP compound to a novel target using an antibody created by Centocor. This license supersedes the previous agreement between the companies.
Under the terms of the agreement, ImmunoGen gains the ...
angiogenesis
antibodies
milestone payments
+2